NCT04469075View on ClinicalTrials.gov

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
GlioblastomaRecurrent GlioblastomaSkin Toxicity
Interventions
DRUG

Clindamycin Phosphate

phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)

DRUG

Triamcinolone Acetonide

triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change

Trial Locations (8)

10021

Memorial Sloan Kettering Cancer Center, New York

10032

Columbia University, New York

11788

Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities), Hauppauge

45219

University of Cincinnati Medical Center, Cincinnati

60208

Northwestern University, Evanston

63110

Washington University School of Medicine, St Louis

02111

Tufts Medical Center, Boston

07601

Hackensack Meridian Health, Hackensack

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER